TTRX News & Events

Turn Therapeutics announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. Within the completed interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in overall eczema severity within 4 weeks compared to 65.2% for vehicle-treated subjects. Additional separation was observed across deeper responder thresholds designed to measure near-clearance of disease, including Week 4 EASI-90 responses of 44.4% for GX-03 versus 30.4% for vehicle, which further increased to 51.9% versus 34.8%, respectively, by Week 8. These findings suggest that a substantial proportion of GX-03-treated subjects experienced rapid and progressively deeper reductions in eczema severity over the course of treatment.

Turn Therapeutics announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36-associated inflammatory environment. The publication, titled "Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression," was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen Bresnick, M.D., a practicing physician, researcher, and advisor to the Company. Study Highlights: GX-03 was evaluated in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression; IL-36 protein expression was confirmed following Staphylococcus aureus exposure, establishing the inflammatory environment in which GX-03 was evaluated; Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls; No treatment-related adverse effects were observed

Turn Therapeutics announced the appointment of Stephen Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration, FDA, to oversee the clinical and regulatory strategy for GX-03, the Company's investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis.

Cash and cash equivalents as of March 31, 2026 were $11.2 million as compared to $5.08 million as of December 31, 2025. "The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially," said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. "With the Avenue Capital facility now in place, we believe the Company is well positioned to advance our clinical programs through multiple near-term catalysts while maintaining focus on disciplined execution. Our Phase 2 trial evaluating GX-03 in moderate-to-severe atopic dermatitis remains on schedule, with an independent committee expected to assess conditional probability of success at the interim analysis and determine whether the study should continue as designed or expand enrollment based on the strength of the observed trend. We continue to expect topline results in mid-2026 and believe these upcoming milestones have the potential to meaningfully shape the future of both our platform and pipeline."